Arca Biopharma (ABIO)
News
| May 25 | In some $ABIO $ZLCS by redkompressor |
| May 25 | $ZLCS $GNOM $ABIO look for these to be strong in the D/T world and long term by JKMWCL |
| May 25 | $ABIO holding it 4 nxt week by redkompressor |
| May 25 | @JKMWCL i agree with you on that one $ABIO by Sterac |
| May 25 | $ABIO whats your long term predictions on this? by Sterac |
| May 25 | $gnom $ABIO making a nice afternoon run, looking to hold .90 at EOD for a steady climb next week. by JKMWCL |
| May 25 | $ABIO Looking for a nice little bump this afternoon. by JKMWCL |
| May 25 | Hot stocks on watch $GENE $VRML $ABIO $GNOM $SWSH $DEXO $BSDM $MOTR $LIVE $SPMD by Ammeo |
| May 24 | RT@GarethSoloway Good accumulation on $ABIO today ahead of ASCO.Should continue to climb the next two weeks. Bonus would be news if it hit. by InTheMoneyStocks |
| May 24 | Good accumulation on $ABIO today ahead of ASCO. Should continue to climb over the next two weeks. Bonus would be news if it hit. by GarethSoloway |
| May 14 | ARCA BIOPHARMA, INC. Files SEC form 10-Q, Quarterly Report |
| Apr 16 | ARCA BIOPHARMA, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a ... |
| Mar 30 | ARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers |
| Mar 27 | ARCA BIOPHARMA, INC. Files SEC form 10-K, Annual Report |
| Mar 27 | Benzinga's Microcap Movers for Monday March 26, 2012 Benzinga |
Profile
Exchange: NASDAQGM Sector: Healthcare Industry: Biotechnology
ARCA biopharma, Inc. is a Colorado-based biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases. ARCA’s principal focus is to develop personalized therapies for the treatment of cardiovascular disease through the use of genetics. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics and clinical development.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Arca Biopharma is down 68.92% over the last year vs S&P 500 Total Return up 2.03%, BioLineRx up 0.00%, and Halozyme Therapeutics up 24.96%.
- ABIO Total Returns
- ^SPXTR Total Returns
- BLRX Total Returns
- HALO Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these ABIO related companies
Pro Strategies Featuring ABIO
Did Arca Biopharma make it into our Pro Portfolio Strategies?
ABIO Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other ABIO Resources
- Company Website
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| ABIO | 0.69 | +0.14 | +25.45% | 7.259M |
| ABH | 11.83 | +0.00 | +0.00% | 1.149B |
| ABFS | 12.99 | +0.15 | +1.17% | 330.60M |
| ABD | 9.40 | -0.08 | -0.84% | 523.11M |
| ACHN | 7.35 | +0.03 | +0.41% | 518.69M |
| ACH | 10.07 | -0.25 | -2.42% | 1.589B |
| ACGL | 38.31 | -0.31 | -0.80% | 5.188B |
| ACG | 8.20 | +0.00 | +0.00% | |
| ACFN | 8.89 | -0.26 | -2.84% | 157.80M |
| ACFCD | 2.18 | +0.33 | +17.84% |
